TP53 and prostate neoplasm: The aggregation phenotypes of p53 observed in breast, ovarian, and prostate tumors have been correlated with p53 dominant-negative and oncogenic gain-of-function activities (Kluth et al., 2014, Lasagna-Reeves et al., 2013, Xu et al., 2011).